Allogeneic CRISPR-edited donor T cells engineered with an anti‑CD19 STAR receptor inserted at the TRAC locus redirect TCR–CD3 signaling to recognize and kill CD19+ B cells independent of MHC. Knockout of TRAC removes the endogenous TCR to reduce GvHD; HLA‑A/B and CIITA knockouts lower allorecognition and host rejection by minimizing MHC I/II expression; and PD‑1 knockout enhances resistance to checkpoint-mediated inhibition, improving antitumor activity against CD19+ malignancies.